Marina Bibikova, PhD (she/her/hers)

Chief Scientific Officer
AnchorDx, Inc.

Marina Bibikova, PhD, Chief Scientific Officer at AnchorDx, Inc.
Biotechnology professional with over 25 years of expertise in molecular biology, biochemistry, genetics and epigenetics. Responsible for cancer early detection technology development, global IVD registrations and strategic partnerships with commercial and research organizations.
Prior to joining AnchorDx, worked at Illumina for over 20 years as Director/Principal Scientist, responsible for the development of both Research and IVD products, covering genotyping, gene expression profiling and DNA methylation analysis, including development and validation of MiSeqDx Open Platform, the first Food and Drug Administration (FDA)-regulated next-generation sequencing (NGS) instrument.

Poster(s):

• (ST019) UriFind® Assay Facilitates the Management of Urothelial Carcinoma in a Large-scale Multicenter Prospective Cohort
  Saturday, November 18, 2023

  9:15 AM – 10:15 AM MST